AR084754A1 - Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso - Google Patents

Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso

Info

Publication number
AR084754A1
AR084754A1 ARP110105031A ARP110105031A AR084754A1 AR 084754 A1 AR084754 A1 AR 084754A1 AR P110105031 A ARP110105031 A AR P110105031A AR P110105031 A ARP110105031 A AR P110105031A AR 084754 A1 AR084754 A1 AR 084754A1
Authority
AR
Argentina
Prior art keywords
express
stem cells
composition
placental stem
composition according
Prior art date
Application number
ARP110105031A
Other languages
English (en)
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of AR084754A1 publication Critical patent/AR084754A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3616—Blood, e.g. platelet-rich plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Abstract

Reivindicación 1: Una composición caracterizada porque comprende células madre placentarias y plasma rico en plaquetas, en donde la composición es adecuada para la inyección a un individuo, y en donde las células madre placentarias se adhieren al plástico para cultivo celular, son CD34-, CD10+, CD105+ y CD200+ y no son trofoblastos.Reivindicación 2: La composición de acuerdo con la reivindicación 1, caracterizada porque las células madre placentarias no se obtienen del cordón umbilical. Reivindicación 3: La composición de acuerdo con la reivindicación 1, caracterizada porque la composición no comprende un sustituto óseo implantable y no requiere trombina para retener las células madre placentarias en un sitio de inyección de dicha composición al individuo. Reivindicación 4: La composición de acuerdo con la reivindicación 1, caracterizada porque la inyección de dicha composición al individuo da como resultado la localización prolongada de las células madre placentarias en el sitio de inyección, con respecto a la inyección de células madre placentarias no combinadas con plasma rico en plaquetas. Reivindicación 5: La composición de acuerdo con la reivindicación 1, caracterizada porque las células madre placentarias expresan CD200 y no expresan HLA-G; o expresan CD73, CD105 y CD200; o expresan CD200 y OCT-4; o expresan CD73 y CD105 y no expresan HLA-G; o expresan CD73 y CD105 y facilitan la formación de uno o más cuerpos de tipo embrionario en una población de células placentarias que comprenden dicha célula madre cuando la población se cultiva en condiciones que permiten la formación de un cuerpo de tipo embrionario; o expresan OCT-4 y facilitan la formación de uno o más cuerpos de tipo embrionario en una población de células placentarias que comprenden dicha célula madre cuando la población se cultiva en condiciones que permiten la formación de cuerpos de tipo embrionario. Reivindicación 9: La composición de acuerdo con la reivindicación 1, caracterizada porque la relación volumen-volumen entre las células madre placentarias y el plasma rico en plaquetas en la composición es de alrededor de 1:1.
ARP110105031A 2010-12-30 2011-12-29 Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso AR084754A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061428721P 2010-12-30 2010-12-30

Publications (1)

Publication Number Publication Date
AR084754A1 true AR084754A1 (es) 2013-06-05

Family

ID=45532031

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110105031A AR084754A1 (es) 2010-12-30 2011-12-29 Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso

Country Status (3)

Country Link
US (1) US20120171161A1 (es)
AR (1) AR084754A1 (es)
WO (1) WO2012092458A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100915482B1 (ko) * 2000-12-06 2009-09-03 하리리 로버트 제이 태반 줄기 세포의 회수 방법
NZ528035A (en) 2001-02-14 2005-07-29 Robert J Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
PL2471904T3 (pl) 2005-12-29 2019-08-30 Celularity, Inc. Populacje komórek macierzystych łożyska
EP2783692B1 (en) 2007-09-28 2019-01-02 Celularity, Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
CN102176919A (zh) 2008-08-22 2011-09-07 人类起源公司 用胎盘细胞群治疗骨缺损的方法和组合物
CA2767014C (en) 2009-07-02 2022-01-25 Anthrogenesis Corporation Method of producing erythrocytes without feeder cells
SI2556145T1 (sl) 2010-04-07 2017-01-31 Anthrogenesis Corporation Angiogeneza z uporabo placentnih matičnih celic
KR20130092394A (ko) 2010-04-08 2013-08-20 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 사르코이드증의 치료
NZ605505A (en) 2010-07-13 2015-02-27 Anthrogenesis Corp Methods of generating natural killer cells
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
EP3443968A1 (en) 2011-06-01 2019-02-20 Celularity, Inc. Treatment of pain using placental stem cells
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
WO2014004609A2 (en) * 2012-06-27 2014-01-03 University Of Medicine & Dentistry Of New Jersey Rapid assays for t-cell activation by rna measurements using flow cytometry
CN113481164A (zh) * 2012-12-14 2021-10-08 人类起源公司 抗失巢凋亡胎盘干细胞及其应用
NL2010225C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for preserving, transporting and storing living biological materials.
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
JP6591395B2 (ja) 2013-03-15 2019-10-16 ジェネンテック， インコーポレイテッド 抗酸化剤を含む細胞培養組成物およびポリペプチド産生のための方法
US20150273215A1 (en) * 2014-03-26 2015-10-01 Pacesetter, Inc. Systems and methods for assessment of pain and other parameters during trial neurostimulation
US20170290861A1 (en) * 2014-09-26 2017-10-12 Anthrogenesis Corporation Treatment of diabetic foot ulcer using placental stem cells
JP2018504395A (ja) * 2014-12-31 2018-02-15 アンソロジェネシス コーポレーションＡｎｔｈｒｏｇｅｎｅｓｉｓ Ｃｏｒｐｏｒａｔｉｏｎ 血小板の分離方法
US9173921B1 (en) 2015-03-23 2015-11-03 Jaehyun Lim Method of promoting hair growth by administration of bFGF
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
US10561684B2 (en) 2015-08-27 2020-02-18 Min Bo SHIM Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma and method using the same
KR101738815B1 (ko) * 2015-08-27 2017-05-23 심민보 혈소판 풍부 혈장을 포함하는 감각신경성 난청 또는 이명을 예방 또는 치료하기 위한 약학적 조성물 및 이를 이용한 방법
TWI676478B (zh) * 2016-05-20 2019-11-11 國璽幹細胞應用技術股份有限公司 一種用以製備治療糖尿病之醫藥組合物及其用途
KR102115960B1 (ko) * 2018-11-28 2020-05-27 송미연 인간 중간엽 줄기세포를 갑상선 호르몬 분비세포로 분화 방법
CN111388649B (zh) * 2020-03-19 2023-09-12 杭州三江上御生物科技有限公司 一种富血小板血浆胎盘多肽组合物及其应用
CN112402365B (zh) * 2020-10-26 2023-10-03 山东博森医学工程技术有限公司 一种用于治疗椎间盘退变疾病的prp凝胶负载脐带间充质干细胞组合物
CN115998668A (zh) * 2021-05-24 2023-04-25 禾美生物科技(浙江)有限公司 脐带间充质干细胞活性肽分泌物、制备方法、应用及皮肤微生态调节剂
CN113398246B (zh) * 2021-06-30 2022-09-20 上海市皮肤病医院 eIF3I-PDL1-IRS4轴在制备难治性溃疡药物中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5552267A (en) 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
US5516532A (en) 1994-08-05 1996-05-14 Children's Medical Center Corporation Injectable non-immunogenic cartilage and bone preparation
US5830708A (en) 1995-06-06 1998-11-03 Advanced Tissue Sciences, Inc. Methods for production of a naturally secreted extracellular matrix
US5654381A (en) 1995-06-16 1997-08-05 Massachusetts Institute Of Technology Functionalized polyester graft copolymers
US6337387B1 (en) 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
EP1194463B1 (en) 1999-04-16 2009-11-11 Wm. MARSH RICE UNIVERSITY Poly(propylene fumarate) cross linked with poly(ethylene glycol)-dimethacrylate
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
KR100915482B1 (ko) 2000-12-06 2009-09-03 하리리 로버트 제이 태반 줄기 세포의 회수 방법
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP1362095B1 (en) 2001-02-14 2015-05-27 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
NZ528035A (en) 2001-02-14 2005-07-29 Robert J Hariri Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
ES2452595T3 (es) 2005-10-13 2014-04-02 Anthrogenesis Corporation Inmunomodulación usando células madre de la placenta
EP1974013A2 (en) 2005-12-29 2008-10-01 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
PL2471904T3 (pl) 2005-12-29 2019-08-30 Celularity, Inc. Populacje komórek macierzystych łożyska
ZA200810412B (en) * 2006-06-09 2010-03-31 Anthrogenesis Corp Placental niche and use thereof to culture stem cells
AU2008216749B2 (en) 2007-02-12 2014-03-13 Celularity Inc. Treatment of inflammatory diseases using placental stem cells
US20100323446A1 (en) * 2009-06-05 2010-12-23 Jill Renee Barnett Method of collecting placental cells
ES2646750T3 (es) * 2010-01-26 2017-12-15 Anthrogenesis Corporation Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias

Also Published As

Publication number Publication date
WO2012092458A2 (en) 2012-07-05
WO2012092458A3 (en) 2012-08-23
US20120171161A1 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
AR084754A1 (es) Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso
AR080030A1 (es) Tratamiento de tipos de cancer oseo mediante el uso de celulas madre placentarias
AR084753A1 (es) Composiciones que comprenden celulas adherentes derivadas del saco amniotico (amdac) y plasma rico en plaquetas (prp)
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
CL2016003096A1 (es) Métodos para cosechar cultivos de células de mamífero
EP2603227A4 (en) IMPROVED HEMATOPOETIC TRIBE AND PRECURSOR CELL THERAPY
WO2012048010A3 (en) Compositions of adult organ stem cells and uses thereof
EP4249916A3 (en) Compositions and methods for non-myeloablative conditioning
BR112014032074A2 (pt) construções de tecido conjuntivo tridimensionais engendradas e métodos de fabricar as mesmas
WO2011130624A3 (en) Sustained polypeptide expression from synthetic, modified rnas and uses thereof
CO2019011450A2 (es) Expresión transgénica selectiva de tejidos
BR112015017174A2 (pt) preparação de enxertos de nervo de tecido manipulado com matriz extracelular modificada para reparo de lesão de nervo periférico
MX2017004890A (es) Metodos y composiciones para la generación o el mantenimiento de células pluripotentes.
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
AR081166A1 (es) Angiogenesis por el uso de celulas madre placentarias
EP3388512A4 (en) METHOD OF SEPARATING AND CULTIVATING MESENCHYMAL STRAIN CELLS FROM THE NECKLACE WHARTON SULPHATE
MY171710A (en) Culture medium composition, and method for culturing cell or tissue using said composition
MX344304B (es) Metodos y composiciones para mejorar la movilizacion de celulas madre.
WO2014053418A3 (en) Method for obtaining mesenchymal stem cells and use thereof
CR20120132A (es) Celulas madre del revestimiento de cordon umbilical y metodos y material para aislar y cultivar las mismas
UY36475A (es) Composiciones y metodos para el uso de insecticida con bacillus sp d747
CR20160307A (es) Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas
BR112015009229A2 (pt) composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada
PH12018502061A1 (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
WO2014186508A8 (en) Human extensively self-renewing erythroblasts (esre)

Legal Events

Date Code Title Description
FB Suspension of granting procedure